Clinical Research Directory
Browse clinical research sites, groups, and studies.
CHiR Therapy for Elderly DLBCL Intolerant to Chemo
Sponsor: First Affiliated Hospital of Ningbo University
Summary
The objective of exploring the application of CHiR is to evaluate its therapeutic efficacy and safety in newly diagnosed elderly patients with diffuse large B-cell lymphoma (DLBCL) aged 70 and above, and to investigate the genetic subtypes that may benefit from CHiR. The primary endpoint is the complete remission rate (CRR) at the end of 8 cycles.
Official title: A Single-arm, Multicenter, Prospective Clinical Study of CHiR (chidamide, Zanubrutinib, and Lenalidomide) for Newly Diagnosed MYC- and BCL2-positive Diffuse Large B-cell Lymphoma (DLBCL) in Elderly Patients Intolerant to Chemotherapy.
Key Details
Gender
All
Age Range
70 Years - 100 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2025-02-01
Completion Date
2027-08-01
Last Updated
2025-03-19
Healthy Volunteers
No
Conditions
Interventions
CHiR-DEL
Using the combined regimen of CHiR (chidamide, zanubrutinib, and lenalidomide) to treat newly diagnosed elderly patients with MYC- and BCL2-expressing positive diffuse large B-cell lymphoma (DLBCL) who are intolerant to chemotherapy.
Locations (1)
The First Affiliated Hospital of Ningbo University
Ningbo, Zhejiang, China